Lung Cancer (NSCLC)

    Genetic Abnormality Prevalence Clinical Experience with Targeted Agent
    ALK/EML4-ALK 2% Crizotinib (ALK/MET inhibitor) (FDA approved):
    • Phase 1: RR 61%, PFS 9.7 mo (1)
    Ceritinib (ALK inhibitor) (FDA approved):
    • Phase 3: PFS 16.6 vs. 8.1 mo for chemotherapy (2)
    Alectinib (ALK inhibitor) (FDA approved):
    • Phase 2: In ALK-positive, crizotinib-resistant NSCLC, 48% OR (3)
    EGFR 12%–15% (mutation in exon 19 or 21) Erlotinib (EGFR inhibitor) (FDA approved):
    • Phase 3 (in pts with exon 19 or 21 deletions or exon 21 mutations): RR 60%–70% vs. 15%–20% with standard chemotherapy. PFS
    Other topics in Targets by Organ Site